NSE filing, NSE: NIDAN. Summary written from the filing by ALFA Finder's alert engine.
Nidan Laboratories And Healthcare Ltd: key numbers
- Share price
- ₹13.00
- Market cap
- ₹18.07 Cr
- Revenue (annual)
- ₹25.54 Cr
- Net profit (annual)
- ₹1.51 Cr
- P/E (TTM)
- 12.0×Sector 52.0×
- Promoter holding
- 57.04%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Nidan Laboratories And Healthcare Ltd
All →Nidan Laboratories And Healthcare Other Announcement
Nidan Laboratories and Healthcare Limited submitted a non-applicability intimation for Corporate Governance reports. The company is exempt under SEBI Regulation 15 due to its SME listing.
Nidan Laboratories And Healthcare Annual General Meeting
Nidan Laboratories and Healthcare Limited conducted its 26th Annual General Meeting on September 28, 2026. Shareholders considered agenda items including financial statement adoption and director re-appointments.
Nidan Laboratories And Healthcare Annual General Meeting
Nidan Laboratories and Healthcare Limited will hold its 26th Annual General Meeting on September 28, 2026. The company has submitted its Annual Report for FY 2025-26.
Nidan Laboratories And Healthcare Annual General Meeting
Nidan Laboratories and Healthcare Limited will convene its 26th Annual General Meeting on September 28, 2026. The board also approved book closure and e-voting schedules.
Nidan Laboratories And Healthcare Board Meeting Date
Nidan Laboratories and Healthcare Limited has scheduled a board meeting for August 20, 2026. The meeting agenda covers general business matters.
Nidan Laboratories And Healthcare Management Change
Nidan Laboratories re-appointed Nilesh Bide and Abhinay Nerurkar as Independent Directors for five-year terms. These appointments ensure continued board stability and regulatory compliance.
- Execution
- 60 months
Other board meeting outcome announcements
All →R R Kabel Board Meeting Outcome
RR Kabel's board approved amendments to its UPSI fair disclosure code on 28 October 2026. The amended code is enclosed and posted on the company website.
M K Exim (India) Board Meeting Outcome
M.K. Exim (India) approved shifting its registered office within Jaipur to Plot J-1247, Sitapura. The board meeting was held on October 28, 2026.
United Spirits Board Meeting Outcome
United Spirits' board approved amendments to its insider trading code on 28 October 2026, effective 29 October 2026. The revised code is available on the company website.
SBI Funds Management Board Meeting Outcome
SBI Funds Management extended internal auditor Chhajed & Doshi's term to March 31, 2030. This routine decision was taken at the October 28, 2026 board meeting.
- Execution
- April 1, 2028 to March 31, 2030
Paras Healthcare Board Meeting Outcome
Paras Healthcare filed its board-approved UPSI fair disclosure code under Regulation 8(2). This routine governance policy update reports no business event.
Gateway Distriparks Board Meeting Outcome
Gateway Distriparks' board approved a revised Code of Practices for Fair Disclosure of UPSI under PIT Regulation 8(2). This is a routine governance policy update with no business event.